Teligent Announces FDA Approval of Desoximetasone Ointment USP 0.05%

Teligent (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Desoximetasone Ointment USP 0.05%.  This is Teligent’s twelfth approval for 2018, and its thirty-first approval from its internally-developed pipeline of topical generic pharmaceutical medicines.

As quoted in the press release:

Based on recent IQVIA data from August 2018, the total addressable market for this product is approximately $7.3 million.

“With this most recent approval, Teligent continues to show its strength in developing products and bringing them successfully through the approval process,’’ commented Jason Grenfell-Gardner, President and CEO of the Company.

Mr. Grenfell-Gardner continued, “We now have thirty-six topical generic pharmaceutical products in the US portfolio, in addition to our four US injectable products.”

Click here to read the full press release.